AU2009214443B2 - Templated open flocs of anisotropic particles for enhanced pulmonary delivery - Google Patents

Templated open flocs of anisotropic particles for enhanced pulmonary delivery Download PDF

Info

Publication number
AU2009214443B2
AU2009214443B2 AU2009214443A AU2009214443A AU2009214443B2 AU 2009214443 B2 AU2009214443 B2 AU 2009214443B2 AU 2009214443 A AU2009214443 A AU 2009214443A AU 2009214443 A AU2009214443 A AU 2009214443A AU 2009214443 B2 AU2009214443 B2 AU 2009214443B2
Authority
AU
Australia
Prior art keywords
particles
hfa
tff
protein
flocculated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009214443A
Other languages
English (en)
Other versions
AU2009214443A1 (en
Inventor
Joshua Engstrom
Keith P. Johnston
Jasmine Tam
Robert O. Williams Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2009214443A1 publication Critical patent/AU2009214443A1/en
Application granted granted Critical
Publication of AU2009214443B2 publication Critical patent/AU2009214443B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009214443A 2008-02-13 2009-02-13 Templated open flocs of anisotropic particles for enhanced pulmonary delivery Ceased AU2009214443B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2821808P 2008-02-13 2008-02-13
US61/028,218 2008-02-13
PCT/US2009/034162 WO2009103035A2 (en) 2008-02-13 2009-02-13 Templated open flocs of anisotropic particles for enhanced pulmonary delivery

Publications (2)

Publication Number Publication Date
AU2009214443A1 AU2009214443A1 (en) 2009-08-20
AU2009214443B2 true AU2009214443B2 (en) 2013-10-10

Family

ID=40955349

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009214443A Ceased AU2009214443B2 (en) 2008-02-13 2009-02-13 Templated open flocs of anisotropic particles for enhanced pulmonary delivery

Country Status (7)

Country Link
US (7) US12263243B2 (enExample)
EP (1) EP2252275B1 (enExample)
AU (1) AU2009214443B2 (enExample)
CA (1) CA2723314C (enExample)
DK (1) DK2252275T3 (enExample)
NO (1) NO2252275T3 (enExample)
WO (1) WO2009103035A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2252275T3 (enExample) 2008-02-13 2018-04-28
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8506799B2 (en) * 2009-09-09 2013-08-13 ClearCorp Suspended particle characterization system for a water processing facility
US9248110B2 (en) 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
WO2011115988A1 (en) * 2010-03-18 2011-09-22 Steven Lehrer Compositions and methods of treating and preventing lung cancer
US9228785B2 (en) 2010-05-04 2016-01-05 Alexander Poltorak Fractal heat transfer device
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN104274426A (zh) * 2013-07-03 2015-01-14 陆克塞纳医药公司 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途
CN104274427A (zh) * 2013-07-03 2015-01-14 陆克塞纳医药公司 格拉司琼气溶胶组合物及其用途
CA2926719C (en) 2013-10-08 2020-11-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN112656780A (zh) 2014-02-20 2021-04-16 奥迪托皮克股份有限公司 用于吸入的干粉制剂
RS64482B1 (sr) 2014-04-04 2023-09-29 Ai Therapeutics Inc Inhalaciona formulacija rapamicina za lečenje stanja povezanih sa starenjem
CN116687887A (zh) 2014-07-31 2023-09-05 维克图拉公司 用于吸入的干粉制剂
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
CA2983427C (en) * 2015-05-01 2024-04-23 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
MX2018002586A (es) 2015-09-01 2020-11-24 First Wave Bio Inc Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala.
US10550019B2 (en) 2016-04-08 2020-02-04 OptikTechnik LLC Automated dosing system and method with light profiling for wastewater filtration system
EP3485215B1 (en) 2016-07-12 2023-06-07 Alexander Poltorak System and method for maintaining efficiency of a heat sink
RU2766086C2 (ru) 2016-10-14 2022-02-07 Пулматрикс Оперэйтинг Компани, Инк. Противогрибковые сухие порошки
CA3083953A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
WO2019204568A1 (en) * 2018-04-20 2019-10-24 Board Of Regents, The University Of Texas System Apparatus and methods for characterizing plume geometry
US12091313B2 (en) 2019-08-26 2024-09-17 The Research Foundation For The State University Of New York Electrodynamically levitated actuator
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
WO2021188564A1 (en) 2020-03-16 2021-09-23 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
EP4125923A1 (en) 2020-04-01 2023-02-08 Board of Regents, The University of Texas System Pharmaceutical compositions of niclosamide
US20220023204A1 (en) * 2020-04-20 2022-01-27 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
EP4158025A1 (en) 2020-05-26 2023-04-05 Gradalis, Inc. Methods for the treatment of viral respiratory infections
WO2022055817A1 (en) 2020-09-09 2022-03-17 Gradalis, Inc. Composition formulated into inhalable dosage forms for the treatment of lung|tumors
US20220362222A1 (en) * 2021-05-12 2022-11-17 Tff Pharmaceuticals, Inc. Once daily formulations of tacrolimus
US20230112956A1 (en) * 2021-08-30 2023-04-13 Board Of Regents, The University Of Texas System Monoclonal antibody dry powders
WO2023034844A1 (en) 2021-08-31 2023-03-09 Board Of Regents, The University Of Texas System Delayed release niclosamide formulation
WO2024059819A2 (en) 2022-09-15 2024-03-21 Tff Pharmaceuticals, Inc. Compositions of cannabinoids for delivery by inhalation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064029A1 (en) * 1997-09-29 2003-04-03 Tarara Thomas E. Engineered particles and methods of use
WO2003090715A2 (en) * 2002-04-25 2003-11-06 Nektar Therapeutics Uk Ltd Particulate materials
WO2005025506A2 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
JPH1112197A (ja) 1997-06-18 1999-01-19 Cosmo Sogo Kenkyusho:Kk 悪性腫瘍診断剤及び治療剤
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
AR028746A1 (es) 2000-06-23 2003-05-21 Norton Health Care Ltd Cartucho de dosis previamente medidas para inhalador de polvo seco accionado por la respiracion, el inhalador y un metodo de provision de dosis previamente medidas de polvo seco
JP2003146523A (ja) 2001-11-15 2003-05-21 Canon Inc 画像形成装置
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
EP1556018A1 (en) 2002-09-30 2005-07-27 Acusphere, Inc. Sustained release porous microparticles for inhalation
AU2003302274A1 (en) * 2002-12-31 2004-07-29 Novartis Ag Aerosolizable pharmaceutical formulation for fungal infection therapy
JP4933732B2 (ja) 2003-01-15 2012-05-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 低温表面上で凍結させることによって得られる薬物粒子
EP1789018A1 (en) 2004-08-27 2007-05-30 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
WO2008144888A1 (en) * 2007-05-25 2008-12-04 The University Of British Columbia Formulations for the oral administration of therapeutic agents and related methods
NO2252275T3 (enExample) 2008-02-13 2018-04-28

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064029A1 (en) * 1997-09-29 2003-04-03 Tarara Thomas E. Engineered particles and methods of use
US7306787B2 (en) * 1997-09-29 2007-12-11 Nektar Therapeutics Engineered particles and methods of use
WO2003090715A2 (en) * 2002-04-25 2003-11-06 Nektar Therapeutics Uk Ltd Particulate materials
WO2005025506A2 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOWER C, et al. 'Fractal morphology of drug aggregates in aerosol propellant suspensions,' International Journal of Pharmaceutics, (1995) Vol 118 pp 229-235 *
STEIN SW, et al. 'The Relative Influence of Atomization and Evaporation on Metered Dose Inhaler Drug Delivery Efficiency,' Aerosol Science and Technology, (2006) Vol 40: 5pp 335-347 *

Also Published As

Publication number Publication date
US20220354778A1 (en) 2022-11-10
AU2009214443A1 (en) 2009-08-20
DK2252275T3 (en) 2018-03-05
US12029816B2 (en) 2024-07-09
US10434062B2 (en) 2019-10-08
US10660850B2 (en) 2020-05-26
CA2723314A1 (en) 2009-08-20
US20100221343A1 (en) 2010-09-02
US20190117557A1 (en) 2019-04-25
EP2252275A4 (en) 2013-11-06
US20210007971A1 (en) 2021-01-14
US20200069572A1 (en) 2020-03-05
WO2009103035A3 (en) 2009-11-12
US20090208582A1 (en) 2009-08-20
WO2009103035A2 (en) 2009-08-20
EP2252275A2 (en) 2010-11-24
US10092512B2 (en) 2018-10-09
NO2252275T3 (enExample) 2018-04-28
US20250127717A1 (en) 2025-04-24
CA2723314C (en) 2017-01-10
US11364197B2 (en) 2022-06-21
EP2252275B1 (en) 2017-11-29
US12263243B2 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
US12029816B2 (en) Compositions and methods of making brittle-matrix particles through blister pack freezing
EP1734938B1 (en) Insulin highly respirable microparticles
Seville et al. Spray-dried powders for pulmonary drug delivery
JP5317960B2 (ja) 微粉砕化有機化合物粒子の製造方法
US6946117B1 (en) Stabilized preparations for use in nebulizers
Tam et al. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution
US9724344B2 (en) Enhanced delivery of drug compositions to treat life threatening infections
US20080038357A1 (en) Inhalation Powder Containing the CGRP antagonist BIBN4096 and Process for the Preparation Thereof
IL135126A (en) Perforated microparticles and methods for using and preparing them
AU1555300A (en) Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
Engstrom et al. Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers
Chan Inhalation drug delivery devices and emerging technologies
Rowe et al. Compositions and methods of making brittle-matrix particles through blister pack freezing
AU2003208862A1 (en) Powder inhalation containing cgrp-antagonist bibn4096 and method for the production thereof
KR102259824B1 (ko) 보센탄을 함유한 약학 제제
CN116617404A (zh) 磷脂作为抑晶剂的用途
Durham et al. Spray dried pyrazinoate salts for tuberculosis therapy

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER NATIONAL PHASE HAS BEEN EXTENDED TO 13 OCT 2010.

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ TAM, JASMINE; ENGSTROM, JOSHUA; JOHNSTON, KEITH P. AND WILLIAMS III, ROBERT O. .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ TAM, JASMINE; ENGSTROM, JOSHUA; JOHNSTON, KEITH P. AND WILLIAMS III, ROBERT O.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired